Blood myelin oligodendrocyte glycoprotein level as an indicator of diagnosis and disease activity in multiple sclerosis

Background and ObjectivesBiomarkers that are informative with regards to the degree of demyelination associated with disease activity in multiple sclerosis may aid in prognostication and treatment considerations. Protein components of myelin, such as myelin oligodendrocyte glycoprotein (MOG), are potential biomarkers of demyelination, but questions remain about the significance and usefulness of blood MOG protein levels in multiple sclerosis. We examined blood MOG protein levels to determine the extent to which MOG levels are associated with the diagnosis and disease activity of multiple sclerosis. MethodsIn a case-control study, MOG protein levels were compared in serum samples from individuals with multiple sclerosis and controls. Cerebrospinal fluid (CSF) MOG protein levels were measured in a subset of the cases. Serum neurofilament light chain (NfL) levels were also measured for comparison. ResultsSerum MOG protein levels were higher in individuals with multiple sclerosis than those of healthy donors and non-inflammatory neurological controls. ROC curve analysis indicated good discrimination between multiple sclerosis and controls based on serum MOG protein levels. Correlation between serum and CSF MOG protein levels was moderate. Higher MOG protein levels were associated with clinical disease activity in multiple sclerosis and incrementally added to information provided by serum NfL levels. There was a moderate correlation between serum MOG and serum NfL levels. DiscussionMOG protein levels are elevated in the blood of individuals with multiple sclerosis and may be associated with disease activity.